Phase 3 Clinical Trials With Primary Completion Dates in March 2024
This is a list of Phase 3 trials with primary completion dates in March 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2024-03-01 | Phase 3 | NCT03121586 | Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia |
| AVIR | Atea Pharmaceuticals, Inc. | 2024-03-01 | Phase 3 | NCT05629962 | SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 |
| BFRI | Biofrontera Inc. | 2024-03-01 | Phase 3 | NCT03573401 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). |
| CERE | Cerevel Therapeutics Holdings, Inc. | 2024-03-01 | Phase 3 | NCT04542499 | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations |
| DCPH | Deciphera Pharmaceuticals, Inc. | 2024-03-01 | Phase 3 | NCT05059262 | Study of Vimseltinib for Tenosynovial Giant Cell Tumor |
| DCTH | Delcath Systems, Inc. | 2024-03-01 | Phase 3 | NCT05022901 | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma |
| JAZZ | Jazz Pharmaceuticals plc | 2024-03-01 | Phase 3 | NCT03897127 | Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics |
| MMSI | Merit Medical Systems, Inc. | 2024-03-01 | Phase 3 | NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant |
| ONPH | Oncology Pharma Inc. | 2024-03-01 | Phase 3 | NCT02194842 | Phase III Radium 223 mCRPC-PEACE III |
| OTLK | Outlook Therapeutics, Inc. | 2024-03-01 | Phase 3 | NCT05112861 | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders |